You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

CLINICAL TRIALS PROFILE FOR VIMOVO


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for VIMOVO

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00527787 ↗ Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen Completed POZEN Phase 3 2007-09-01 This study uses a randomized, double-blind, controlled design to demonstrate that PN400 (esomeprazole and naproxen) is more effective in reducing the occurrence of gastroduodenal ulcers, dyspepsia, and heartburn in subjects at risk for developing NSAID-associated gastric ulcers compared to naproxen alone.
NCT00527904 ↗ A 12-month, Phase 3, Open-label, Multi-center Study to Evaluate the Long-term Safety of PN400 (VIMOVO) Completed POZEN Phase 3 2007-03-01 This study uses an open-label design and will be conducted in approximately 60 sites aiming to enroll a total number of 200 subjects to ensure that at least 100 subjects will have 12 months exposure to PN400 (VIMOVO).
NCT00594854 ↗ Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers in High Risk Subjects Compared to Arthrotec Terminated POZEN Phase 3 2007-09-01 This randomized, double-blind, parallel-group, controlled, multi-center clinical trial of 6 months duration is designed to assess the efficacy, tolerability and safety of PN400 versus diclofenac/misoprostol in subjects at high risk for developing NSAID-associated gastric ulcers. Approximately 100 sites will participate to enroll a total of 200 subjects (100 per arm). At least 20% of the subjects enrolled will be age 65 years and older.
NCT00664560 ↗ Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis Completed POZEN Phase 3 2008-04-01 We will evaluate the efficacy of PN400 and an active comparator in patients that have Osteoarthritis of the knee.
NCT00665431 ↗ Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis Completed POZEN Phase 3 2008-04-01 We will evaluate the efficacy of PN 400 and an active comparator in patients that have Osteoarthritis of the knee.
NCT01129011 ↗ Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen Completed POZEN Phase 3 2007-09-01 This study uses a randomized, double-blind, controlled design to demonstrate that PN400 (esomeprazole and naproxen) is more effective in reducing the occurrence of gastroduodenal ulcers, dyspepsia, and heartburn in subjects at risk for developing NSAID-associated gastric ulcers compared to naproxen alone.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for VIMOVO

Condition Name

Condition Name for VIMOVO
Intervention Trials
Gastric Ulcer 4
Osteoarthritis 2
Acute and Chronic Inflammation 1
Bioequivalence 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for VIMOVO
Intervention Trials
Stomach Ulcer 4
Ulcer 3
Arthritis, Juvenile 2
Arthritis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for VIMOVO

Trials by Country

Trials by Country for VIMOVO
Location Trials
United States 19
Korea, Republic of 1
Brazil 1
United Kingdom 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for VIMOVO
Location Trials
North Carolina 5
District of Columbia 1
Colorado 1
California 1
Arkansas 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for VIMOVO

Clinical Trial Phase

Clinical Trial Phase for VIMOVO
Clinical Trial Phase Trials
Phase 4 1
Phase 3 7
Phase 2 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for VIMOVO
Clinical Trial Phase Trials
Completed 9
Unknown status 1
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for VIMOVO

Sponsor Name

Sponsor Name for VIMOVO
Sponsor Trials
POZEN 6
AstraZeneca 2
Horizon Pharma Ireland, Ltd., Dublin Ireland 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for VIMOVO
Sponsor Trials
Industry 10
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.